LoviTest | Maxwellia

In February 2024, Maxwellia announced the launch of LoviTest™ a convenient at-home STI testing service for chlamydia and gonorrhoea, building on our direct-to-consumer (D2C) sexual health offering, lovima.com, and complementing our over-the-counter contraception brands Lovima® and LoviOne®.

LoviTest™ is designed for the detection of genital chlamydia and gonorrhoea infections, and gives users the convenience and discretion of at-home testing. The kit provides options for either a urine sample or a vaginal swab, ensuring a hassle-free sample collection process, along with free return postage, and results within 48-hours of the sample being received.

Recent statistics highlight the need for greater awareness and access to STI testing solutions. In 2022 alone, there were 392,4531 diagnoses of new STIs in England, representing a significant increase of 23.8% compared to the previous year. Specifically, chlamydia diagnoses increased by 24.3%, reaching 199,233 cases in 20221, while gonorrhoea diagnoses surged by 50.3%, totalling 82,592 cases.

Maxwellia has partnered with a fellow Catapult Ventures portfolio business, Biofortuna, to deliver the tests and sample analysis. Deeside based Biofortuna is a specialist outsourcing partner for a range of genomic and testing services.

Speaking about the launch, Maxwellia's CEO Anna Maxwell stated:

"With the alarming rise in STI diagnoses, there's an evident demand for accessible and confidential testing solutions. LoviTest™ empowers individuals to take charge of their sexual health from the comfort and privacy of their own homes. We are committed to providing innovative and effective solutions to support overall sexual health and wellbeing."

Learn more about LoviTest™ at Lovima.com.